Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...

Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...

"The prognosis was so poor that the hospital called in grief counsellors to speak with my family and help prepare them." ...

Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...

Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy Compared with CRSa, CRS-HIPEC improved ...

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...

CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...